Kyntra Bio (KYNB) FCF Margin (2014 - 2026)
Kyntra Bio (KYNB) posted FCF Margin of 371.51% for Q1 2026, up 74.12% sequentially from 1435.24% in Q4 2025, and down 47019.0% YoY from N/an in Q1 2025.
Kyntra Bio (KYNB) FCF Margin (2014 - 2026) Analysis & Trends
Kyntra Bio has reported FCF Margin for 13 years, with the latest figure at 371.51% in Q1 2026.
- Quarterly FCF Margin fell 47019.0% year-over-year to 371.51% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 287.7% (up 90419.0% YoY) and the FY2025 annual result came in at 74.72%, up 39206.0% from the prior year.
- FCF Margin climbed to 371.51% in Q1 2026 per KYNB's latest filing, from 1435.24% in the prior quarter.
- Over five years, FCF Margin peaked at 939.84% in Q2 2025 and troughed at 9970.75% in Q2 2024.
- A 5-year average of 1739.9% and a median of 371.51% in 2026 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2024 and 2025: FCF Margin slumped 919600 bps in 2024, then surged 1091059 bps in 2025.
- Over 5 years, FCF Margin stood at 589.68% in 2022, then jumped by 104 bps to 21.89% in 2023, then plunged by 4560 bps to 976.3% in 2024, then plunged by 47 bps to 1435.24% in 2025, then jumped by 74 bps to 371.51% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 371.51%, 1435.24%, and 172.49% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.47 Bn | 131.61 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 86.36 Bn | 78.37 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 65.16 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.99 Bn | 53.85 Bn | 52.00 Mn | -388.28% |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 25.68% |
| 6 | Alnylam Pharmaceuticals | 31.74 Bn | 28.43 Bn | 992.69 Mn | 22.62% |
| 7 | BioNTech SE | 28.01 Bn | 9.61 Bn | 668.28 Mn | 41.07% |
| 8 | Insmed | 27.50 Bn | 26.34 Bn | 358.27 Mn | -22.35% |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 70.82% |
| 10 | Kyntra Bio | 29.96 Mn | 29.96 Mn | 1.47 Mn | -270.76% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -270.76% |
| Mar 31, 2026 | -371.51% |
| Dec 31, 2025 | -1,435.24% |
| Sep 30, 2025 | -172.49% |
| Jun 30, 2025 | 939.84% |
| Mar 31, 2025 | 98.69% |
| Dec 31, 2024 | -976.30% |
| Sep 30, 2024 | -6,876.42% |
| Jun 30, 2024 | -9,970.75% |
| Mar 31, 2024 | -2,696.23% |
| Dec 31, 2023 | 21.89% |
| Sep 30, 2023 | -212.34% |
| Jun 30, 2023 | -774.75% |
| Mar 31, 2023 | -6,010.71% |
| Dec 31, 2022 | -589.68% |
| Sep 30, 2022 | -335.21% |
| Jun 30, 2022 | -113.97% |
| Mar 31, 2022 | -103.20% |
| Dec 31, 2021 | -340.66% |
| Sep 30, 2021 | 27.36% |